Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

Inclusion Criteria:

- Advanced lymphoid leukemia (primary refractory ALL; Relapsed ALL; CML in lymphoid
accelerated phase or blast crisis; relapsed or refractory Burkitt's lymphoma;
relapsed or refractory T-cell adult leukemia/lymphoma; relapsed or refractory
lymphoblastic lymphoma

- >= 18 and <= 65 years of age ECOG performance status 0, 1 Life expectancy >= 4 weeks
Able to consume oral medication Required initial laboratory values: Creatinine <=
2.0mg/dL, total or direct bilirubin <= 1.5 mg/dL, SGPT(ALT) <=ULN, glucose < 200
mg/dL, negative pregnancy test for women with child bearing potential

Exclusion Criteria:

- Subjects must not be receiving any chemotherapy agents (except Hydroxyurea)

- Subjects must not have received high-dose Ara-C within 6 months of relapse

- Subjects must not be receiving growth factors, except for erythropoietin

- No currently active second malignancy other than non-melanoma skin cancers

- No subjects with uncontrolled high blood pressure, unstable angina, symptomatic
congestive heart failure, MI within the last 6 months or serious uncontrolled cardiac
arrhythmia

- Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort,
Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil,
Tacrolimus

- Known HIV positivity or AIDS-related illness

- Evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with
Ara-C administration

- Pregnant or lactating

- Uncontrolled infection

- Taking fluconazole, voriconazole, itraconazole and ketoconazole currently or within
one week of study entry